Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
Description
Digital Care Made Human™. Omada® enables individuals to reach their health aspirations through enduring lifestyle modifications. Our all-encompassing digital care ensures that engaging in various programs is simple, as we provide your workforce with round-the-clock, tailored support to meet their unique health requirements. Prediabetes Prevention: An alarming 1 in 3 Americans is affected by prediabetes. With Omada’s Prevention program, participants can expect a 30% reduction in the risk of Type 2 Diabetes and a 13% decrease in heart disease risk. On average, those who complete the program shed around 4-5% of their body weight and maintain this loss over time. Diabetes Management: A concerning 46% of diabetes patients fail to achieve proper glycemic control (A1C < 7%). In Omada’s Diabetes program, 92% of participants express satisfaction, and those who were not meeting their goals saw an A1C reduction of over 1%. Additionally, with Hypertension affecting 46% of the US population, our programs are designed to address this significant health challenge effectively. Our commitment to ongoing support ensures that individuals can take charge of their health journey with confidence.
API Access
Has API
API Access
Has API
Integrations
Collective Health
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/
Vendor Details
Company Name
Omada Health
Country
United States
Website
www.omadahealth.com
Product Features
Product Features
Corporate Wellness
Activity Tracking
Employee Portal
Financial Wellness
Gamification
Goal Setting / Tracking
Health Coaching
Health Monitoring
Health Risk Assessment
Incentive Management
Program Management